Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline Seynaeve

Showing results (71-80 of 175) with videos related to

Pageof 18
Sort By:
European Journal of Cancer (Oxford, England : 1990)|May 12, 2017
HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2John M S Bartlett, Ikhlaaq Ahmed, Meredith M Regan, et al.
BMC Cancer|July 25, 2008
A family history of breast cancer will not predict female early onset breast cancer in a population-based settingGeertruida H de Bock, Catharina E Jacobi, Caroline Seynaeve, et al.
NPJ Breast Cancer|June 27, 2017
Molecular stratification of early breast cancer identifies drug targets to drive stratified medicineJane Bayani, Cindy Q Yao, Mary Anne Quintayo, et al.
Hereditary Cancer in Clinical Practice|April 3, 2009
Standard psychological consultations and follow up for women at increased risk of hereditary breast cancer considering prophylactic mastectomyMurly B M Tan, Eveline M A Bleiker, Marian B E Menke-Pluymers, et al.
The Oncologist|December 25, 2012
Elderly postmenopausal patients with breast cancer are at increased risk for distant recurrence: a tamoxifen exemestane adjuvant multinational study analysisWillemien van de Water, Caroline Seynaeve, Esther Bastiaannet, et al.
Breast Cancer Research and Treatment|June 29, 2002
One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery)Litanja N Lodder, Petra G Frets, R Willem Trijsburg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology studyJohn M S Bartlett, Kenneth J Bloom, Tammy Piper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer CentreMarijke Bontenbal, Geert-Jan Creemers, Hans J Braun, et al.
Breast Cancer Research and Treatment|February 3, 2012
MUTYH gene variants and breast cancer in a Dutch case–control studyAstrid A Out, Marijke Wasielewski, Petra E A Huijts, et al.
NPJ Breast Cancer|July 9, 2021
Comparative survival analysis of multiparametric tests-when molecular tests disagree-A TEAM Pathology studyJohn M S Bartlett, Jane Bayani, Elizabeth Kornaga, et al.
Pageof 18

Showing results (71-80 of 175) with videos related to

Sort By:
Pageof 18
European Journal of Cancer (Oxford, England : 1990)|May 12, 2017
HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2John M S Bartlett, Ikhlaaq Ahmed, Meredith M Regan, et al.
BMC Cancer|July 25, 2008
A family history of breast cancer will not predict female early onset breast cancer in a population-based settingGeertruida H de Bock, Catharina E Jacobi, Caroline Seynaeve, et al.
NPJ Breast Cancer|June 27, 2017
Molecular stratification of early breast cancer identifies drug targets to drive stratified medicineJane Bayani, Cindy Q Yao, Mary Anne Quintayo, et al.
Hereditary Cancer in Clinical Practice|April 3, 2009
Standard psychological consultations and follow up for women at increased risk of hereditary breast cancer considering prophylactic mastectomyMurly B M Tan, Eveline M A Bleiker, Marian B E Menke-Pluymers, et al.
The Oncologist|December 25, 2012
Elderly postmenopausal patients with breast cancer are at increased risk for distant recurrence: a tamoxifen exemestane adjuvant multinational study analysisWillemien van de Water, Caroline Seynaeve, Esther Bastiaannet, et al.
Breast Cancer Research and Treatment|June 29, 2002
One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery)Litanja N Lodder, Petra G Frets, R Willem Trijsburg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology studyJohn M S Bartlett, Kenneth J Bloom, Tammy Piper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer CentreMarijke Bontenbal, Geert-Jan Creemers, Hans J Braun, et al.
Breast Cancer Research and Treatment|February 3, 2012
MUTYH gene variants and breast cancer in a Dutch case–control studyAstrid A Out, Marijke Wasielewski, Petra E A Huijts, et al.
NPJ Breast Cancer|July 9, 2021
Comparative survival analysis of multiparametric tests-when molecular tests disagree-A TEAM Pathology studyJohn M S Bartlett, Jane Bayani, Elizabeth Kornaga, et al.
Pageof 18